Extending the Breast Cancer Surveillance Consortium Model of Invasive Breast Cancer
Journal of Clinical Oncology · 2024-03 · 42 (7) · 779-789
DOI: 10.1200/jco.22.02470 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2024-03. Verfasst von Charlotte C Gard und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Economics, Applied Statistics, and International Business, New Mexico State University, Las Cruces, NM. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, AHRQ HHS.
Abstract (Originalsprache)
PURPOSE We extended the Breast Cancer Surveillance Consortium (BCSC) version 2 (v2) model of invasive breast cancer risk to include BMI, extended family history of breast cancer, and age at first live birth (version 3 [v3]) to better inform appropriate breast cancer prevention therapies and risk-based screening. METHODS We used Cox proportional hazards regression to estimate the age- and race- and ethnicity-specific relative hazards for family history of breast cancer, breast density, history of benign breast biopsy, BMI, and age at first live birth for invasive breast cancer in the BCSC cohort. We evaluated calibration using the ratio of expected-to-observed (E/O) invasive breast cancers in the cohort and discrimination using the area under the receiver operating characteristic curve (AUROC). RESULTS We analyzed data from 1,455,493 women age 35-79 years without a history of breast cancer. During a mean follow-up of 7.3 years, 30,266 women were diagnosed with invasive breast cancer. The BCSC v3 model had an E/O of 1.03 (95% CI, 1.01 to 1.04) and an AUROC of 0.646 for 5-year risk. Compared with the v2 model, discrimination of the v3 model improved most in Asian, White, and Black women. Among women with a BMI of 30.0-34.9 kg/m 2 , the true-positive rate in women with an estimated 5-year risk of 3% or higher increased from 10.0% (v2) to 19.8% (v3) and the improvement was greater among women with a BMI of ≥35 kg/m 2 (7.6%-19.8%). CONCLUSION The BCSC v3 model updates an already well-calibrated and validated breast cancer risk assessment tool to include additional important risk factors. The inclusion of BMI was associated with the largest improvement in estimated risk for individual women.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Economics, Applied Statistics, and International Business, New Mexico State University, Las Cruces, NM.
- Division of General Internal Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA.
- University of California, Davis, Davis, CA.
- Kaiser Permanente Washington Health Research Institute, Seattle, WA.
- Department of Surgery, University of Vermont Cancer Center, Burlington, VT.
- Department of Radiology, University of Vermont Cancer Center, Burlington, VT.
ORCID-Profile: Charlotte C Gard, Jeffrey A Tice, Diana L Miglioretti, Michael C S Bissell, Karla Kerlikowske
Förderung
- NCI NIH HHS
- AHRQ HHS
Zitieren
APA
Gard, C. C., Tice, J. A., Miglioretti, D. L., Sprague, B. L., Bissell, M. C. S., Henderson, L. M., & Kerlikowske, K. (2024). Extending the Breast Cancer Surveillance Consortium Model of Invasive Breast Cancer. Journal of Clinical Oncology, 42(7), 779-789. https://doi.org/10.1200/jco.22.02470
Vancouver
Gard CC, Tice JA, Miglioretti DL, Sprague BL, Bissell MCS, Henderson LM, et al. Extending the Breast Cancer Surveillance Consortium Model of Invasive Breast Cancer. Journal of Clinical Oncology. 2024;42(7):779-789. doi:10.1200/jco.22.02470
BibTeX
@article{Gard2024,
author = {Gard, Charlotte C and Tice, Jeffrey A and Miglioretti, Diana L and Sprague, Brian L and Bissell, Michael C S and Henderson, Louise M and Kerlikowske, Karla},
title = {Extending the Breast Cancer Surveillance Consortium Model of Invasive Breast Cancer},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {7},
pages = {779--789},
doi = {10.1200/jco.22.02470}
}
EUVIMED